Exelon (Alzheimer’s Disease)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.2 Symptoms 27
4 Disease Management 29
4.1 Diagnosis 29
4.1.1 Probable Alzheimer’s Disease Dementia 30
4.1.2 Possible AD Dementia 31
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 32
4.1.5 Preclinical AD 32
4.1.6 Mild Cognitive Impairment 33
4.2 Treatment Overview 35
5 Competitive Assessment 38
5.1 Overview 38
5.2 Strategic Competitor Assessment 38
6 Exelon (rivastigmine, rivastigmine tartrate) 41
6.1 Overview 41
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 45
6.5 Forecast 45
7 Appendix 47
7.1 Bibliography 47
7.2 Abbreviations 52
7.3 Methodology 55
7.4 Forecasting Methodology 55
7.4.1 Diagnosed AD patients 55
7.4.2 Percent Drug-treated Patients 57
7.4.3 General Pricing Assumptions 57
7.4.4 Individual Drug Assumptions 58
7.4.5 Generic Erosion 58
7.5 Physicians and Specialists Included in this Study 59
7.6 About the Authors 60
7.6.1 Author 60
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61